The Chronic Urticaria Registry CURE. International Steering Committee (ISC) Charter

Similar documents
THOMSON REUTERS CORPORATE GOVERNANCE COMMITTEE CHARTER

1. Number. Except as otherwise permitted by the applicable NASDAQ rules, the Audit Committee shall consist of at least three members of the Board.

SIGMA DESIGNS, INC. CORPORATE GOVERNANCE GUIDELINES. (As adopted by the Board of Directors effective as of June 2012)

AGL ENERGY LIMITED BOARD CHARTER 1. PURPOSE 2. ROLE AND RESPONSIBILITIES OF BOARD

DIAMOND OFFSHORE DRILLING, INC. Corporate Governance Guidelines

MAGNA INTERNATIONAL INC. BOARD CHARTER

CORPORATE GOVERNANCE GUIDELINES

COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION. Audit Committee Charter. Updated December 12, 2017

Audit Committee Charter

Audit Committee. Terms of Reference. Jo Bieda LME.COM/CLEAR. LME CLEAR LIMITED 10 Finsbury Square, London EC2A 1AJ Tel +44 (0)

CHARTER OF THE AUDIT COMMITTEE NATIONWIDE MUTUAL INSURANCE COMPANY NATIONWIDE MUTUAL FIRE INSURANCE COMPANY NATIONWIDE CORPORATION

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DROPBOX, INC.

BOARD OF DIRECTORS CHARTER

AUTODESK, INC. CORPORATE GOVERNANCE GUIDELINES. Adopted December 15, Most Recently Amended December 15, 2016

Author Statements and Copyright Assignment

GLENVEAGH PROPERTIES PLC REMUNERATION AND NOMINATION COMMITTEE TERMS OF REFERENCE

AMENDED AND RESTATED ON SEMICONDUCTOR CORPORATION CORPORATE GOVERNANCE PRINCIPLES

CISCO SYSTEMS, INC. CORPORATE GOVERNANCE POLICIES

BOARD CHARTER TOURISM HOLDINGS LIMITED

CGIAR System Management Board Audit and Risk Committee Terms of Reference

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF PAM TRANSPORTATION SERVICES, INC.

OPTINOSE, INC. CORPORATE GOVERNANCE GUIDELINES

II. Funding of Guideline Development Direct funding of evidence-based guideline production by medical and pharmaceutical industry is prohibited.

AUDIT COMMITTEE CHARTER

Corporate Governance Guidelines of Audi Private Bank sal

METHANEX CORPORATION CORPORATE GOVERNANCE PRINCIPLES

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network

BTG plc Terms of Reference of the Remuneration Committee ( Committee ) of the Board of Directors ( Board ) of BTG plc ( Company )

SUNEDISON, INC. AUDIT COMMITTEE CHARTER (Adopted October 29, 2008)

Board Charter Z Energy Limited

MSC INDUSTRIAL DIRECT CO., INC. Corporate Governance Guidelines

RISK AND AUDIT COMMITTEE TERMS OF REFERENCE

CDK GLOBAL, INC. AUDIT COMMITTEE CHARTER Effective January 20, 2016

Audit Committee Charter

BOARD OF DIRECTORS MANDATE

NATIONAL VISION HOLDINGS, INC. CORPORATE GOVERNANCE GUIDELINES

BOARD OF DIRECTORS RYDER SYSTEM, INC. CORPORATE GOVERNANCE GUIDELINES

irobot Corporation Audit Committee Charter I. General Statement of Purpose

CITIZENS, INC. AMENDED AND RESTATED AUDIT COMMITTEE CHARTER. Adopted November 5, the integrity of the Company s financial statements;

Corporate Governance Principles. As Amended June 7, 2017

Remuneration & Nominations Committee Charter. Pendal Group Limited ABN

PPG INDUSTRIES, INC. AUDIT COMMITTEE CHARTER

BrightPath Early Leaning Inc. Audit Committee Charter

CONSTITUTION OF THE GLOBAL ALLIANCE FOR GENOMICS AND HEALTH. Adopted, 2014

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF MULESOFT, INC.

CHARTER OF THE REGULATORY OVERSIGHT COMMITTEE FOR THE GLOBAL LEGAL ENTITY IDENTIFIER (LEI) SYSTEM

AUDIT COMMITTEE. each member must be financially literate (as determined by the Board);

IMMUNOGEN, INC. CORPORATE GOVERNANCE GUIDELINES OF THE BOARD OF DIRECTORS

LLOYDS BANKING GROUP AUDIT COMMITTEE TERMS OF REFERENCE (LLOYDS BANKING GROUP PLC, LLOYDS BANK PLC, BANK OF SCOTLAND PLC & HBOS PLC)

Kathy O Kane Kreutzer, M.Ed., Office of Faculty Affairs, School of Medicine March, 2017

Audit and Risk Committee Charter

FARMER BROS. CO. CORPORATE GOVERNANCE GUIDELINES (Adopted February 1, 2017)

CHARTER OF THE BOARD OF DIRECTORS

JACOBS ENGINEERING GROUP INC. CORPORATE GOVERNANCE GUIDELINES

APOGEE ENTERPRISES, INC. CORPORATE GOVERNANCE GUIDELINES

HYDRO ONE LIMITED CORPORATE GOVERNANCE GUIDELINES

AUDIT COMMITTEE CHARTER. Specifically, the Audit Committee is responsible for overseeing that:

AUDIT COMMITTEE TERMS OF REFERENCE

GOVERNANCE GUIDELINES FOR THE BOARD OF DIRECTORS

NORFOLK SOUTHERN CORPORATION. Committee s Role and Purpose

TG Therapeutics, Inc. Audit Committee Charter

Audit Committee Charter for XL Group Ltd

Invest In Your Future: Volunteer Today. SGNA Leadership Opportunities

Audit Committee of the Board of Directors Charter CNL HEALTHCARE PROPERTIES II, INC.

Five-step Authorship Framework to Improve Transparency in Disclosing Contributors to Industry-Sponsored Publications. LaVerne Mooney, DrPH

GOLD FIELDS LIMITED. ( GFI or the Company ) BOARD CHARTER. (Approved by the Board of Directors on 16 August 2016)

Bayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans

EASTMAN CHEMICAL COMPANY. Corporate Governance Guidelines

Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)

GENESIS GROUP HOLDINGS, INC. CORPORATE GOVERNANCE POLICIES OF THE BOARD OF DIRECTORS

INTUIT INC. CORPORATE GOVERNANCE PRINCIPLES FOR THE BOARD OF DIRECTORS as amended July 20, 2017

AUDIT COMMITTEE CHARTER

CANADIAN NATURAL RESOURCES LIMITED (the Corporation ) BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES

INTEL CORPORATION BOARD OF DIRECTORS GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES

CITIZENS BANCORP CITIZENS BANK BOARD AUDIT COMMITTEE CHARTER

ANZ Audit Committee Charter

COLGATE-PALMOLIVE COMPANY AUDIT COMMITTEE CHARTER

RDA Secretary General Recruitment

H.E.S.T. Australia Limited. (as Trustee for the Health Employees Superannuation Trust Australia) Governance Disclosures

GTT COMMUNICATIONS, INC. AUDIT COMMITTEE CHARTER

Criteria For Selecting Members Of The Board Of Directors

AUDIT COMMITTEE CHARTER

ABCANN GLOBAL CORPORATION CORPORATE GOVERNANCE POLICIES AND PROCEDURES

BOARD OF DIRECTORS GUIDELINES

China Southern Airlines Company Limited Terms of Reference of Audit and Risk Management Committee

Rules of Procedure Supervisory Board Koninklijke Philips N.V.

SHAW COMMUNICATIONS INC. BOARD OF DIRECTORS MANDATE

GROUP 1 AUTOMOTIVE, INC. AUDIT COMMITTEE CHARTER

AEGON N.V. AUDIT COMMITTEE CHARTER

REQUEST FOR PROPOSALS EXECUTIVE SEARCH SERVICES. Issuance Date November 27, 2017

POLARIS INDUSTRIES INC.

BioAmber Inc. Audit Committee Charter

AUDIT COMMITTEE CHARTER REINSURANCE GROUP OF AMERICA, INCORPORATED. the audits of the Company s financial statements;

CORPORATE GOVERNANCE POLICIES. Board Charter. Accountabilities

Audit Committee Charter

CORPORATE GOVERNANCE GUIDELINES PRICESMART, INC.

Corporate Governance Guidelines of Bank Audi sal

BOARD OF DIRECTORS MANDATE

AXT, INC. CORPORATE GOVERNANCE GUIDELINES

Sunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners. Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd

Transcription:

The Chronic Urticaria Registry CURE International Steering Committee (ISC) Charter

Introduction The Chronic Urticaria Registry (CURE) is an open-ended patient registry for chronic urticaria that collects quality, real-world data, providing us with further understanding of chronic urticaria and its treatment. CURE is an urticaria network e.v. (UNEV) project, endorsed by the urticaria taskforces of the European Academy of Allergy and Clinical Immunology (EAACI) and the Global Asthma and Allergy European Network (GA 2 LEN) as well as the World Allergy Organization (WAO) and the European Academy of Dermatology and Venereology (EADV). International Steering Committee Role and Responsibilities The international Steering Committee (ISC) is the decision-making body in CURE and is established to: Identify scientifically and/or clinically relevant publications (manuscripts, abstracts, posters) generated from the CURE database and develop those publications. Coordinate all data exploration, analyses and peer-reviewed manuscripts, abstracts and other scientific publications generated from the CURE database. Facilitate dissemination of the results in timely and appropriate format. Discuss and make recommendations for future data exploration and analyses/types of data to be collected Decide on the addition of variables to the registry as suggested by the CURE-partners Decide on the acceptance of new CURE-partners / cooperations with CURE-partners Structure of the CURE ISC The CURE ISC is comprised of CURE Investigators. The total number of ISC members should not exceed twenty. The structure of the ISC will be as follows: 1 chair and 1 co-chair (must be from different countries), nominated and voted on by the ISC CURE ISC Charter version 21 JUL 2016 2

1 principal (coordinating) investigator, nominated by ISC Up to 1 member per country/region participating in CURE The period of office for ISC members, the chair, the co-chair, and the principal investigator is 2 years (with an option of renewal as agreed by the ISC) Renewal and change of the ISC: The renewal of the ISC will occur every 2 years. Decisions can be made and voting can take place only if at least two thirds of the Committee members are present and two thirds of the votes are in favour of a proposal. Potential new ISC members need to apply for membership. For becoming a member, a two third majority vote of the ISC is required. Meeting frequency: The ISC will meet twice a year. Members who are not able to attend a meeting can be represented by another investigator from another site or a co-investigator of his/her site from her/his Country or Region. Processes for Decision-Making and Voting by the ISC Processes for ISC decision-making and voting will be as follows: Decisions can be made and voting can take place only if at least two thirds of the ISC members are present and two thirds of the votes are in favour of a proposal. At least the chair or co-chair and the principal investigator must be present for a valid vote to be cast. ISC members who are not able to attend a meeting in person will be invited to vote either through videoconferencing (e.g. Skype), through their delegate or by post/email. If they do not respond to the invitation within a certain timeframe (specified in the letter of invitation to vote), a decision may be taken by the chair and co-chair. Processes for Data Analyses and Interpretation Reports containing descriptive information, as well as analyses of CURE patient data, will be provided for information to CURE investigators and eligible partners at regular intervals. In addition to these regular descriptive data summaries, the capability exists to conduct specific analyses of scientific or clinical interest on the CURE database. CURE ISC Charter version 21 JUL 2016 3

Specific analyses of CURE data can be proposed by any investigator participating in CURE who has entered at least 30 baseline data sets and corresponding follow up data sets (number is subject to annual review by ISC). The proposals will be handled by the CURE principal investigator and (if practicable within the constraints of the database) put forward for consideration by the ISC. The analyses will be overseen by the ISC or by an appointed investigator(s), and carried out by an ISC member or an appointed investigator(s) / biostatistician(s). It is the responsibility of the ISC to approve the use of global data for publications and to collectively agree on the interpretation of data analyses, where relevant. If a publication results from data analyses of global data, the following general rules for coauthorship of the CURE centres apply: 1) if equal or more than 50 baseline data sets and corresponding follow up data sets were entered, the respective centre is automatically asked for co-authorship (one co-author). 2) if equal or more than 100 baseline data sets and corresponding follow up data sets were entered, the respective centre is automatically asked for co-authorship (two co-authors possible). For being part of the author team the criteria of authorship (as set forth in ANNEX 2) have to be met. All other centres, not involved with a co-author, need to be mentioned (acknowledged) in the publication. CURE Investigators may request information (raw data) from the database for their own study centres for their own use. Requests that may be of general interest should be forwarded to the CURE ISC through the principal investigator (Annex 1). CURE Investigators may request information about all data in her/his Country/Region. Such requests should be forwarded to the CURE ISC through the principal investigator. The responses of the CURE ISC will be forwarded to the investigators by the corresponding National/Regional ISC member. The details of the scientific publications activities including global publication, development process and guidelines for authorship are specified in Annex 2. The funding and reimbursement of ISC members is specified in Annex 3. CURE ISC Charter version 21 JUL 2016 4

Conflicts of Interest The members of the ISC should not undertake any other activity which could affect their independent judgment in the performance of their duties, or which conflicts with (or could reasonably give the appearance of conflicting with) the interests of CURE. This does not preclude membership on advisory boards of pharmaceutical companies, receiving honoraria for lectures or consulting, membership on the executive boards of other disease registries or other scientific committees, but such activities should be included in the regular descriptive CURE data summaries as potential conflicts of interests. Confidential Information All ISC members shall be aware that the information they receive may be of confidential nature, and that they may not make use of, or disclose, such confidential information for any other purpose than for performing their duties as ISC members. Role of the urticaria network e.v. UNEV has developed and maintains the CURE database. UNEV has the right and the obligation to use the information in the database in relation to the authorities. UNEV owns the CURE data. UNEV retains the right to evaluate data within CURE and may perform any such evaluations with the approval of the ISC. UNEV has overall responsibility for all statistical work on CURE National and International data. CURE ISC Charter version 21 JUL 2016 5

Annex 1 Date: Request for Analysis Requesting investigator: Name: Affiliation: Address: E-mail: Tel: Fax: Working title: Description of Project and requested analysis: AIM: HYPOTHESIS OF INTEREST: POPULATION(S) OF INTEREST: (e.g. all patients/ children/ adults/treated/untreated) 1. 2. 3. GROUPS OF INTEREST: (e.g. sex, age groups 0-50, >50 etc) CURE ISC Charter version 21 JUL 2016 6

The analysis should be based on data from: All countries* Selected countries** Selected Country** Selected clinic(s)** Data needed by (DD/MM/YYYY): (Normally at least 3 months are needed for answering a request) * Analysis of International data has to be approved by the CURE ISC ** Analysis of National data has to be approved by the National member of the CURE ISC (where applicable), and selected clinics before the request is executed. Purpose: Manuscript Oral presentation Abstract Other. Result will be presented at:. By.. Submitted to (state target journal).. First author:.. Co-authors Other reason for request. Note also the following regulations: The CURE ISC must always approve manuscripts before they are submitted to the journal publisher if it is based on International data. At least one member of the ISC must be involved as a coauthor. CURE and supporting partners must be acknowledged. The CURE National ISC Member and the Investigators in the participating clinics must additionally approve manuscripts based on data from one country. In case of any questions please contact: karsten.weller@charite. CURE ISC Charter version 21 JUL 2016 7

Annex 2 Scientific Publication Activities Global publications: The International Steering Committee (ISC) will develop and maintain the overall CURE Publication Plan based on available CURE data: The overall CURE Publication Plan is based on an evaluation of the available data within the CURE database, expected timelines for further data to accrue/analyses to become available, assessments of the current scientific literature. The ISC is responsible to identify scientifically and/or clinically relevant publications (manuscripts, abstracts, posters) generated from the CURE database and develop those publications. The ISC will have oversight of all concepts and proposals for publications to ensure scientific accuracy and appropriateness. International summaries and analyses of CURE data must not be published by the National/Regional Boards or disclosed to any outside entities without the agreement of the ISC. The CURE Publication Plan will be shared with all investigators regularly (intended is on an annual basis) Copies of published CURE manuscripts may be made available to the CURE investigators by the ISC. Country/Regional publications: All country/regional publication development will be under the supervision of the corresponding National/Regional member of the CURE ISC (if not available by an appointed member of the ISC). The respective member or the ISC will determine if and how the results of regional CURE analyses and data summaries should be published. A copy of any publication for a country/regional publication should be sent to the ISC prior to submission at least twenty-one (21) days prior to submitting an abstract, manuscript or other document for publication or presentation. Site publication: Each participating investigator/study site is free to use and publish their own data, and also has the right to veto pooling of their data for scientific publications (apart from regular descriptive data summaries, which cannot be vetoed). A standardised Request for Analyses form for CURE Investigators to request specific analyses from data set is available from the CURE principal investigator. A copy of any publication for an individual investigator/study site using CURE data should be sent to the ISC prior to submission at least twenty-one (21) days prior to submitting an abstract, manuscript or other document for publication or presentation. CURE ISC Charter version 21 JUL 2016 8

All publications and presentations of the individual site results shall appropriately reference the multi-site study registry publication, if any, or the fact that the individual site registry results are a subset of data resulting from a larger multi-site study registry. Publication development process: CURE follows Good Publication Practice 2 (GPP2) guidelines (www.gpp-guidelines.org). Members of the International Steering Committee may become authors, but membership of the committee does not automatically confer authorship (BMJ 2009;339:b4330; doi: 10.1136/bmj.b4330.) UNEV can facilitate professional writing and editorial assistance from a third party which can, under the direction of the ISC, assist with; the drafting or editing of publications (manuscript, abstract, poster) drawing figures and graphs, performing literature searches, manuscript submission Guidelines for Authorship of publications arising from CURE Authorship is attributed according to the International Committee of Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/). Authorship selection for each publication activity of national or international data (manuscripts, abstracts, posters) is to be agreed by all members of the ISC. All authors of CURE publications will be required to provide full disclosures of their financial interests in line with the international Good Publications Practice 2 (GPP2) guidelines for reporting medical research. To be listed as an author, you must meet all 3 of the following criteria: Substantial contributions to design, acquisition of data, or analysis and interpretation of data Drafting the publication or revising it critically for important intellectual content Final approval of the version to be published Positions of administrative leadership, contributing patients to the study and collecting and preparing data for analysis, however important to the research, are not by themselves criteria for authorship. The ISC will determine prior to the initiation of the publication which author should take the lead for writing and managing each publication or presentation (i.e. lead author). One author should take overall responsibility for the integrity of a study and its report. CURE ISC Charter version 21 JUL 2016 9

Annex 3 Funding and reimbursement ISC members ISC members will not be rewarded with honoraria or other fees for participating as a member or an author. Reasonable travel expenses however to attend CURE meetings can be reimbursed, depending on the funding obtained for CURE. CURE ISC Charter version 21 JUL 2016 10